Current Oncology Reports

, Volume 5, Issue 4, pp 263–264 | Cite as

Limitations to the use of the CA-125 antigen level in ovarian cancer

  • Maurie Markman
Editor’s Commentary
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Markman M: The role of CA-125 in the management of ovarian cancer. Oncologist 1997, 2:6–9.PubMedGoogle Scholar
  2. 2.
    Rustin GJS, Nelstrop AE, McClean P, et al.: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996, 14:1545–1551.PubMedGoogle Scholar
  3. 3.
    Bridgewater JA, Nelstrop AE, Rustin GJS, et al.: Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 1999, 17:501–508.PubMedGoogle Scholar
  4. 4.
    Rustin GJS, Nelstrop AE, Tuxen MK, et al.: Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group study. Ann Oncol 1996, 7:361–364.PubMedGoogle Scholar
  5. 5.
    Rubin SC, Hoskins WJ, Hakes TB, et al.: Serum CA-125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 1989, 160:667–671.PubMedGoogle Scholar
  6. 6.
    Atack DB, Nisker JA, Allen HH, et al.: CA 125 surveillance and second-look laparotomy in ovarian carcinoma. Am J Obstet Gynecol 1986, 154:287–289.PubMedGoogle Scholar
  7. 7.
    Markman M: Follow-up of the asymptomatic patient with ovarian cancer. Gynecol Oncol 1994, 55:S134-S137.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Maurie Markman
    • 1
  1. 1.Department of Hematology/Medical OncologyThe Cleveland Clinic FoundationClevelandUSA

Personalised recommendations